---
title: "Peptide Library research profiles"
canonical_url: https://bestpeptidecalculator.app/library
description: "208 research profiles covering mechanism, half-life, side effects, regulatory status and cited studies."
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Peptide Library research profiles

- [5-Amino-1MQ](https://bestpeptidecalculator.app/library/5-amino-1mq.md): Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug.
- [Abaloparatide](https://bestpeptidecalculator.app/library/abaloparatide.md): FDA-approved parathyroid hormone–related peptide analog (Tymlos) for postmenopausal osteoporosis at high fracture risk.
- [ACE-031](https://bestpeptidecalculator.app/library/ace-031.md): Fusion protein of the activin receptor type IIB extracellular domain with an IgG1 Fc region, developed as a myostatin pathway inhibitor for muscular dystrophy. Clinical development was discontinued after vascular adverse events. Not FDA-approved.
- [Acetyl Hexapeptide-8](https://bestpeptidecalculator.app/library/acetyl-hexapeptide-8.md): Topical hexapeptide (Argireline) used in cosmetics as a SNAP-25 fragment analog. Marketed to soften expression lines; not an FDA-approved drug.
- [Acetyl Octapeptide-3](https://bestpeptidecalculator.app/library/acetyl-octapeptide-3.md): Elongated Argireline analog (SNAP-8) used in topical cosmetics. Not an FDA-approved drug; not WADA-prohibited as a cosmetic peptide.
- [Acetyl Tetrapeptide-3](https://bestpeptidecalculator.app/library/acetyl-tetrapeptide-3.md): Short acetylated tetrapeptide used topically in hair-density and skin-firmness formulations, commonly paired with red clover extract in commercial blends. Regulated as a cosmetic ingredient, not FDA-approved as a drug.
- [Adamax](https://bestpeptidecalculator.app/library/adamax.md): Adamantane-modified Semax analog sold for nootropic research. No study of Adamax is indexed in PubMed; its proposed neurotrophic and stability benefits are design intent carried over from Semax. No FDA approval; human PK is not established.
- [Adipotide](https://bestpeptidecalculator.app/library/adipotide.md): Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug.
- [Afamelanotide](https://bestpeptidecalculator.app/library/afamelanotide.md): FDA-approved α-MSH analog implant (SCENESSE) to increase pain-free light exposure in adults with erythropoietic protoporphyria.
- [AHK-Cu](https://bestpeptidecalculator.app/library/ahk-cu.md): Alanine-histidine-lysine copper complex used in hair- and skin-cosmetic research, related to GHK-Cu. Not an FDA-approved drug.
- [AICAR](https://bestpeptidecalculator.app/library/aicar.md): Adenosine analog studied as an AMP-activated protein kinase activator in metabolic and exercise-physiology research. Not FDA-approved. It is prohibited in sport under the WADA gene and metabolic modulators category.
- [Amycretin](https://bestpeptidecalculator.app/library/amycretin.md): Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.
- [Anamorelin](https://bestpeptidecalculator.app/library/anamorelin.md): Orally active ghrelin receptor agonist developed for cancer cachexia and approved for that use in Japan. It has not been approved by the FDA, which cited insufficient evidence of functional benefit.
- [Angiotensin (1-7) Analog](https://bestpeptidecalculator.app/library/ang-1-7-analog.md): Synthetic Mas-receptor agonist related to angiotensin-(1-7) biology, studied in cardiometabolic and fibrosis models. Not FDA-approved.
- [Angiotensin II](https://bestpeptidecalculator.app/library/angiotensin-ii.md): Synthetic form of the endogenous octapeptide hormone, approved to raise blood pressure in adults with septic or other distributive shock.
- [AOD-9604](https://bestpeptidecalculator.app/library/aod-9604.md): Modified C-terminal hGH fragment studied for lipolysis without GH-receptor growth effects. Not FDA-approved. WADA prohibits GH fragments including AOD-9604 (S2).
- [ARA 290 (Cibinetide)](https://bestpeptidecalculator.app/library/ara-290.md): Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.
- [Atosiban](https://bestpeptidecalculator.app/library/atosiban.md): Oxytocin receptor antagonist used in Europe and elsewhere as a tocolytic to delay imminent preterm birth. It is not approved by the FDA in the United States.
- [ATX-304](https://bestpeptidecalculator.app/library/atx-304.md): Investigational oral small-molecule AMPK activator, formerly O304, tested in two small human trials in type 2 diabetes and in obesity with prediabetes. Not FDA-approved. Prohibited in sport as an AMPK activator under WADA S4.4.1.
- [B7-33](https://bestpeptidecalculator.app/library/b7-33.md): Single-chain relaxin-2 analog designed at Monash University as an RXFP1 agonist for anti-fibrotic and vasodilatory research. Preclinical; not FDA-approved.
- [BAM15](https://bestpeptidecalculator.app/library/bam15.md): Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide.
- [Biotinoyl Tripeptide-1](https://bestpeptidecalculator.app/library/biotinoyl-tripeptide-1.md): Biotin-conjugated tripeptide used in topical hair and lash products, typically as part of proprietary blends. Not FDA-approved as a drug; regulated as a cosmetic ingredient.
- [Bivalirudin](https://bestpeptidecalculator.app/library/bivalirudin.md): FDA-approved bivalent direct thrombin inhibitor used with PCI. IV bolus plus infusion per labeled weight-based regimen; hospital use only.
- [Bonomarlot](https://bestpeptidecalculator.app/library/bonomarlot.md): Peptide preparation derived from bone marrow tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Bonomarlot itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [BPC-157](https://bestpeptidecalculator.app/library/bpc-157.md): Synthetic gastric pentadecapeptide widely sold as a research chemical for tissue-repair models. Not FDA-approved. FDA lists it among bulk substances nominated for compounding and then withdrawn, and FDA staff's May 2026 briefing proposed not adding it to the 503A Bulks List, citing limited safety and effectiveness data. WADA prohibits BPC-157 under S0.
- [Bremelanotide](https://bestpeptidecalculator.app/library/bremelanotide.md): FDA-approved melanocortin agonist (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
- [Bronchogen](https://bestpeptidecalculator.app/library/bronchogen.md): Short synthetic tetrapeptide marketed as a Khavinson bronchial/lung bioregulator. Papers give its sequence as Ala-Glu-Asp-Leu (AEDL) or Ala-Asp-Glu-Leu (ADEL). Russian literature only; not FDA-approved.
- [Cagrilintide](https://bestpeptidecalculator.app/library/cagrilintide.md): Long-acting amylin analog from Novo Nordisk in Phase 3 obesity programs, including the CagriSema combination with semaglutide. Not FDA-approved as of 2026.
- [CagriSema](https://bestpeptidecalculator.app/library/cagrisema.md): Fixed-dose combination of cagrilintide plus semaglutide in Novo Nordisk Phase 3 REDEFINE programs. Not FDA-approved as of 2026.
- [Calcitonin Salmon](https://bestpeptidecalculator.app/library/calcitonin-salmon.md): Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause.
- [Carbetocin](https://bestpeptidecalculator.app/library/carbetocin.md): Long-acting synthetic oxytocin analog used in many countries to prevent uterine atony and postpartum haemorrhage after caesarean delivery. It is not approved by the FDA in the United States.
- [Cardiogen](https://bestpeptidecalculator.app/library/cardiogen.md): Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.
- [Cartalax](https://bestpeptidecalculator.app/library/cartalax.md): Ala-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series, marketed for cartilage and connective-tissue research. Like others in the series it is proposed to act by influencing transcription in the tissue it is associated with, a hypothesis supported almost entirely by cell-culture and cytogenetic work from one research group. No controlled clinical evidence exists for joint or cartilage outcomes, and it is not FDA-approved.
- [Cerebrolysin](https://bestpeptidecalculator.app/library/cerebrolysin.md): Peptide hydrolysate prepared from porcine brain tissue, supplied as a mixture of low-molecular-weight peptides and free amino acids rather than a single characterised compound. It is used in several countries in Europe and Asia for stroke, traumatic brain injury and dementia, where it is given by injection. Not FDA-approved in the United States, and because it is a mixture its composition is not standardised the way a single-entity drug would be.
- [Cerluten](https://bestpeptidecalculator.app/library/cerluten.md): Peptide preparation derived from brain and central nervous system tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Cerluten itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [Cetrorelix](https://bestpeptidecalculator.app/library/cetrorelix.md): GnRH receptor antagonist approved to prevent premature luteinising hormone surges in women undergoing controlled ovarian stimulation.
- [Chondromix](https://bestpeptidecalculator.app/library/chondromix.md): Marketed cartilage-support peptide blend rather than a single characterised active ingredient, with composition varying between suppliers. Because it is a mixture, no single mechanism, sequence or pharmacokinetic profile applies to it, and no pivotal trial has evaluated any branded product under this name. Not FDA-approved and not a treatment for arthritis or joint disease.
- [Chonluten](https://bestpeptidecalculator.app/library/chonluten.md): Glu-Asp-Gly, a synthetic tripeptide in the Khavinson bioregulator series, sold as a bronchial and lung bioregulator. The proposed tissue-specific activity rests on older Russian-language cytogenetic work that has not been independently replicated, and no receptor or signalling pathway has been characterised. There is no modern randomised trial evidence for respiratory outcomes, and it is not FDA-approved.
- [CJC-1295](https://bestpeptidecalculator.app/library/cjc-1295.md): GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues).
- [CJC-1295 (no DAC) / Mod GRF(1-29)](https://bestpeptidecalculator.app/library/cjc-1295-no-dac.md): Modified GRF(1-29), a growth hormone-releasing hormone analog carrying four amino-acid substitutions that resist enzymatic breakdown but without the drug affinity complex group that makes the DAC version long-acting. It is short-acting — its half-life is commonly estimated at about thirty minutes, although no published human study has measured it — rather than producing the multi-day elevation of DAC-CJC, and the two are pharmacologically distinct despite the shared name. Not FDA-approved. Prohibited in sport under WADA class S2.
- [CJC-1295 (no DAC) + Ipamorelin](https://bestpeptidecalculator.app/library/cjc-1295-ipamorelin.md): Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.
- [Cortagen](https://bestpeptidecalculator.app/library/cortagen.md): Ala-Glu-Asp-Pro, a synthetic tetrapeptide in the Khavinson bioregulator series associated with cerebral cortex tissue. Reported findings concern cortical neuron protein synthesis and nerve regeneration in animal models, published largely in Russian-language journals by a single research group without independent replication. No controlled human evidence exists, and it is not FDA-approved.
- [Cortexin](https://bestpeptidecalculator.app/library/cortexin.md): Cattle-cortex polypeptide extract used in some CIS countries as a nootropic. Not FDA-approved; composition is a hydrolysate, not a single peptide.
- [Corticorelin](https://bestpeptidecalculator.app/library/corticorelin.md): Synthetic ovine corticotropin-releasing hormone approved as a diagnostic agent to help distinguish pituitary from ectopic sources of ACTH in ACTH-dependent Cushing syndrome.
- [Cosyntropin](https://bestpeptidecalculator.app/library/cosyntropin.md): Synthetic peptide comprising the first 24 amino acids of corticotropin, approved as a diagnostic agent for screening adrenocortical insufficiency. It is a diagnostic tool rather than a therapy.
- [Cotadutide](https://bestpeptidecalculator.app/library/cotadutide.md): AstraZeneca GLP-1/glucagon receptor dual agonist studied for NASH and type 2 diabetes. Clinical development has been mixed; not FDA-approved.
- [Cranoluten](https://bestpeptidecalculator.app/library/cranoluten.md): Peptide preparation extracted from brain tissue and sold as a central nervous system bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence or mechanism can be assigned and batch composition is not standardised. No study of Cranoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators. It is not FDA-approved.
- [Dasiglucagon](https://bestpeptidecalculator.app/library/dasiglucagon.md): FDA-approved glucagon analog (Zegalogue) for severe hypoglycemia in people with diabetes who weigh at least 20 kg. A ready-to-use rescue injection; Drugs@FDA lists both presentations as discontinued.
- [Davunetide](https://bestpeptidecalculator.app/library/davunetide.md): Eight-amino-acid fragment of activity-dependent neuroprotective protein, investigated for tauopathies. A phase 3 trial in progressive supranuclear palsy did not meet its endpoints and development for that indication stopped. Not FDA-approved.
- [Decapeptide-12](https://bestpeptidecalculator.app/library/decapeptide-12.md): Synthetic decapeptide used topically in pigmentation products as a non-hydroquinone alternative. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
- [Degarelix](https://bestpeptidecalculator.app/library/degarelix.md): Gonadotropin-releasing hormone receptor antagonist approved for advanced hormone-sensitive prostate cancer. Unlike GnRH agonists it lowers testosterone without an initial surge.
- [Delta Sleep-Inducing Peptide (DSIP)](https://bestpeptidecalculator.app/library/dsip.md): Nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reported effects on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier is debated. Research use only and not FDA-approved.
- [Desmopressin](https://bestpeptidecalculator.app/library/desmopressin.md): Synthetic vasopressin analog approved for central diabetes insipidus, primary nocturnal enuresis, nocturia, and for raising factor VIII and von Willebrand factor in mild haemophilia A and type 1 von Willebrand disease.
- [Difelikefalin](https://bestpeptidecalculator.app/library/difelikefalin.md): Peripherally restricted kappa opioid receptor agonist approved for moderate-to-severe pruritus associated with chronic kidney disease in adults on haemodialysis.
- [Dihexa](https://bestpeptidecalculator.app/library/dihexa.md): Orally active angiotensin IV analog that potentiates HGF/c-Met signaling in animal memory models. Not FDA-approved; human safety is not established.
- [Dipeptide Diaminobutyroyl Benzylamide Diacetate](https://bestpeptidecalculator.app/library/syn-ake.md): Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug.
- [Dulaglutide](https://bestpeptidecalculator.app/library/dulaglutide.md): FDA-approved once-weekly GLP-1 Fc-fusion peptide (Trulicity) for type 2 diabetes and CV risk reduction in eligible T2D populations.
- [Ecnoglutide](https://bestpeptidecalculator.app/library/ecnoglutide.md): Investigational long-acting GLP-1 receptor agonist in clinical development for obesity and type 2 diabetes, studied primarily in China. Not FDA-approved.
- [Efpeglenatide](https://bestpeptidecalculator.app/library/efpeglenatide.md): Long-acting exendin-based GLP-1 receptor agonist studied for type 2 diabetes and cardiovascular and renal outcomes. Not FDA-approved.
- [Elamipretide (SS-31)](https://bestpeptidecalculator.app/library/elamipretide.md): Mitochondria-targeted tetrapeptide. FDA granted accelerated approval in September 2025 to Forzinity (elamipretide) to improve muscle strength in Barth syndrome patients ≥30 kg. Confirmatory trial required.
- [Endoluten](https://bestpeptidecalculator.app/library/endoluten.md): Peptide preparation derived from pineal tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Endoluten itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [Enfuvirtide](https://bestpeptidecalculator.app/library/enfuvirtide.md): FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients.
- [Enlicitide](https://bestpeptidecalculator.app/library/enlicitide.md): FDA-approved oral macrocyclic peptide (Lipfendra, July 2026) that blocks PCSK9 to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
- [Epitalon](https://bestpeptidecalculator.app/library/epitalon.md): Synthetic pineal tetrapeptide (AEDG) from Khavinson’s work on epithalamin. Studied for telomerase and circadian research; not FDA-approved.
- [Eptifibatide](https://bestpeptidecalculator.app/library/eptifibatide.md): Cyclic heptapeptide platelet aggregation inhibitor approved for acute coronary syndrome and for patients undergoing percutaneous coronary intervention.
- [Etelcalcetide](https://bestpeptidecalculator.app/library/etelcalcetide.md): Peptide calcimimetic approved for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. It is given intravenously at the end of dialysis rather than orally.
- [Exenatide](https://bestpeptidecalculator.app/library/exenatide.md): Synthetic form of exendin-4 and the first GLP-1 receptor agonist approved in the United States, marketed as Byetta (twice daily) and Bydureon (extended release). Approved as an adjunct to diet and exercise for glycaemic control in type 2 diabetes.
- [Follistatin-344](https://bestpeptidecalculator.app/library/follistatin-344.md): Isoform of follistatin that binds myostatin/activin. Gene-therapy and research-peptide forms exist; no FDA-approved follistatin drug. WADA prohibits myostatin inhibitors (S4).
- [FOXO4-DRI](https://bestpeptidecalculator.app/library/foxo4-dri.md): D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim.
- [Ganirelix](https://bestpeptidecalculator.app/library/ganirelix.md): Synthetic decapeptide GnRH receptor antagonist approved to prevent premature luteinising hormone surges in women undergoing controlled ovarian hyperstimulation.
- [GDF-11](https://bestpeptidecalculator.app/library/gdf-11.md): Circulating member of the TGF-beta superfamily that became prominent in ageing research after parabiosis experiments, and whose reported rejuvenative effects have since been actively disputed. Not FDA-approved; no human trials.
- [GH Fragment 176-191](https://bestpeptidecalculator.app/library/gh-frag-176-191.md): C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).
- [GHK-Cu (Copper Peptide)](https://bestpeptidecalculator.app/library/ghk-cu.md): Endogenous glycyl-L-histidyl-L-lysine copper complex used widely in cosmetics for skin remodeling. Injectable research use is unapproved. USADA lists GHK (tripeptide-1) as not prohibited.
- [GHRP-1](https://bestpeptidecalculator.app/library/ghrp-1.md): Synthetic hexapeptide growth hormone secretagogue from the same series as GHRP-2 and GHRP-6. Not FDA-approved and less studied than either. Human pharmacokinetic data is limited.
- [GHRP-2 + Ipamorelin Blend](https://bestpeptidecalculator.app/library/ghrp2-ipamorelin-combo.md): Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination.
- [GHRP-6](https://bestpeptidecalculator.app/library/ghrp-6.md): Synthetic hexapeptide growth hormone secretagogue and one of the earliest compounds in its class. It raises growth hormone through the ghrelin receptor, and because that is the receptor ghrelin uses to signal hunger it also produces marked appetite stimulation and increased gastric motility, along with rises in cortisol and prolactin. Those off-target effects prompted development of more selective agents such as ipamorelin. Not FDA-approved. Prohibited in sport under WADA class S2.
- [Glow (GHK-Cu / BPC-157 / TB-500)](https://bestpeptidecalculator.app/library/glow.md): Vendor blend typically combining GHK-Cu, BPC-157, and TB-500 for cosmetic/regenerative research. Not a single API; BPC-157 and TB-500 are WADA issues if the blend contains them.
- [Glucagon](https://bestpeptidecalculator.app/library/glucagon.md): Endogenous 29-amino-acid pancreatic hormone, approved as an emergency treatment for severe hypoglycaemia and as a diagnostic aid to inhibit gastrointestinal motility during imaging. Available as injection and nasal powder.
- [Glutathione](https://bestpeptidecalculator.app/library/glutathione.md): Endogenous antioxidant tripeptide sold as an oral supplement and used IV in clinics. Not FDA-approved as a standalone drug for systemic “detox” or skin-lightening claims.
- [Gonadorelin](https://bestpeptidecalculator.app/library/gonadorelin.md): Native GnRH decapeptide used as a diagnostic and, historically, pulsatile therapeutic. WADA prohibits GnRH and analogues (S2).
- [Goserelin](https://bestpeptidecalculator.app/library/goserelin.md): Depot GnRH receptor agonist approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablation.
- [Hexarelin (Examorelin)](https://bestpeptidecalculator.app/library/hexarelin.md): Potent GHRP (examorelin) that raises GH and can desensitize with frequent use. Also studied for cardiac GHSR effects. Not FDA-approved. WADA S2.
- [Histrelin](https://bestpeptidecalculator.app/library/histrelin.md): GnRH receptor agonist delivered from a subcutaneous implant, approved for central precocious puberty in children and for palliative treatment of advanced prostate cancer.
- [Human Chorionic Gonadotropin (hCG)](https://bestpeptidecalculator.app/library/hcg.md): FDA-approved LH-analog glycoprotein for ovulation induction and selected male hypogonadism uses. WADA prohibits hCG in males at all times (S2). Not approved for weight loss.
- [Human Growth Hormone (Somatropin)](https://bestpeptidecalculator.app/library/somatropin.md): FDA-approved recombinant 191-aa human growth hormone for GH deficiency and other labeled indications. WADA prohibits GH at all times (S2).
- [Humanin](https://bestpeptidecalculator.app/library/humanin.md): A 24-amino-acid peptide encoded within the mitochondrial 16S ribosomal RNA gene and one of the first mitochondrial-derived peptides described. It has been studied for cytoprotective signalling, particularly resistance to apoptosis and to oxidative and amyloid stress, and for effects on insulin sensitivity. Circulating concentrations decline with age, which drives much of the interest in it. Research use only, with no human interventional trials and no FDA-approved use.
- [Humanin-G (HNG)](https://bestpeptidecalculator.app/library/humanin-g.md): Analog of the mitochondrial-derived peptide humanin carrying a serine-to-glycine substitution at position 14, reported in preclinical work to be substantially more potent than the parent peptide. Not FDA-approved; no human trials.
- [Icatibant](https://bestpeptidecalculator.app/library/icatibant.md): Selective bradykinin B2 receptor antagonist approved for acute attacks of hereditary angioedema in adults and adolescents. It can be self-administered.
- [IGF-1 (overview)](https://bestpeptidecalculator.app/library/igf-1.md): Endogenous growth factor. Recombinant mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency. Research vials are unapproved. WADA S2.
- [IGF-1 DES](https://bestpeptidecalculator.app/library/igf-1-des.md): IGF-1 lacking the first three amino acids, with reduced IGFBP binding and higher local potency in research models. Not FDA-approved. WADA S2.
- [IGF-1 LR3](https://bestpeptidecalculator.app/library/igf-1-lr3.md): Modified analog of insulin-like growth factor 1 carrying an arginine substitution at position 3 plus a thirteen-residue N-terminal extension, both of which reduce binding to IGF binding proteins. With less of the peptide sequestered, a larger free fraction remains available to the IGF-1 receptor and activity persists longer than native IGF-1. It is a research reagent with no approved use and no controlled human safety data. Prohibited in sport under WADA class S2.
- [Ipamorelin](https://bestpeptidecalculator.app/library/ipamorelin.md): Pentapeptide ghrelin-receptor agonist noted for GH release with relatively less ACTH/cortisol than older GHRPs. Not FDA-approved. WADA S2 (named).
- [Kisspeptin-10](https://bestpeptidecalculator.app/library/kisspeptin-10.md): Decapeptide KISS1 fragment that stimulates GnRH release. Used in reproductive-endocrine research. WADA lists kisspeptin and agonists as S2. Not FDA-approved.
- [Kisspeptin-54 (Metastin)](https://bestpeptidecalculator.app/library/kisspeptin-54.md): Full-length product of the KISS1 gene, originally described as metastin for its reported suppression of tumour metastasis. It acts on hypothalamic neurons upstream of GnRH release and is a gatekeeper of puberty and reproductive axis function; loss-of-function mutations in its receptor cause failure of puberty. It has been used in human reproductive-endocrine research, where its longer sequence gives a somewhat greater duration of action than kisspeptin-10. Not FDA-approved. Prohibited in sport under WADA class S2.
- [Klotho](https://bestpeptidecalculator.app/library/klotho.md): Transmembrane and soluble anti-aging protein that is an FGF23 co-receptor. Shop “Klotho” vials are not an FDA-approved drug and are often fragments or poorly characterized proteins.
- [KLOW (GHK-Cu / KPV / BPC-157 / TB-500)](https://bestpeptidecalculator.app/library/klow.md): Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.
- [KPV](https://bestpeptidecalculator.app/library/kpv.md): C-terminal α-MSH tripeptide with anti-inflammatory activity in gut and skin models without strong melanotropic tanning. Not FDA-approved.
- [Lanreotide](https://bestpeptidecalculator.app/library/lanreotide.md): Long-acting somatostatin analog approved for acromegaly, for unresectable gastroenteropancreatic neuroendocrine tumours, and for carcinoid syndrome.
- [Larazotide](https://bestpeptidecalculator.app/library/larazotide.md): Orally administered octapeptide investigated as an adjunct to a gluten-free diet in coeliac disease. It acts locally in the intestinal lumen. Not FDA-approved.
- [Leuprolide](https://bestpeptidecalculator.app/library/leuprolide.md): FDA-approved GnRH agonist for prostate cancer, endometriosis, and central precocious puberty. Causes pituitary downregulation after an initial flare. WADA S2 (GnRH analogues).
- [Libidon](https://bestpeptidecalculator.app/library/libidon.md): Peptide preparation derived from prostate tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Libidon itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [Linaclotide](https://bestpeptidecalculator.app/library/linaclotide.md): Orally administered 14-amino-acid peptide approved for irritable bowel syndrome with constipation and for chronic idiopathic constipation. It acts locally in the gut lumen and is minimally absorbed systemically.
- [Liraglutide](https://bestpeptidecalculator.app/library/liraglutide.md)
- [Livagen](https://bestpeptidecalculator.app/library/livagen.md): Short synthetic peptide marketed as a hepatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. Published work is largely Russian-language and class-level, and no controlled human trials evaluating this specific peptide for liver outcomes have been indexed.
- [Lixisenatide](https://bestpeptidecalculator.app/library/lixisenatide.md): Once-daily short-acting GLP-1 receptor agonist derived from exendin-4, approved for glycaemic control in adults with type 2 diabetes and also formulated in fixed-ratio combination with insulin glargine.
- [LL-37](https://bestpeptidecalculator.app/library/ll-37.md): Human host-defense peptide (cathelicidin) with antimicrobial and immunomodulatory activity. Not FDA-approved as a drug; excess LL-37 is implicated in rosacea/psoriasis biology.
- [Lonapegsomatropin](https://bestpeptidecalculator.app/library/lonapegsomatropin.md): Once-weekly prodrug of somatropin approved for paediatric growth hormone deficiency, designed to release unmodified growth hormone rather than to act as a modified analog.
- [Macimorelin](https://bestpeptidecalculator.app/library/macimorelin.md): Orally active ghrelin receptor agonist approved as a diagnostic agent for adult growth hormone deficiency. It is the first oral alternative to the insulin tolerance test for this indication.
- [Maridebart cafraglutide](https://bestpeptidecalculator.app/library/maridebart-cafraglutide.md): Amgen bispecific molecule (GIPR antagonist + GLP-1R agonist) in Phase 2/3 obesity development. Monthly-class PK in trials. Not FDA-approved.
- [Mazdutide](https://bestpeptidecalculator.app/library/mazdutide.md): Dual agonist at the GLP-1 and glucagon receptors, developed principally in China and approved there by the National Medical Products Administration in 2025 for weight management and type 2 diabetes. It combines incretin-driven appetite reduction with glucagon-driven increases in hepatic energy expenditure. It has not been reviewed or approved by the FDA and is not available as a prescription medicine in the United States.
- [Mecasermin](https://bestpeptidecalculator.app/library/mecasermin.md): Recombinant human insulin-like growth factor 1 approved for severe primary IGF-1 deficiency and for growth hormone gene deletion with neutralising antibodies to growth hormone.
- [Melanotan II](https://bestpeptidecalculator.app/library/melanotan-ii.md): Cyclic α-MSH analog used illicitly for tanning and libido. Not FDA-approved. FDA and EMA have warned against its use. WADA S0 as a non-approved substance.
- [Methylene Blue](https://bestpeptidecalculator.app/library/methylene-blue.md): Phenothiazine dye approved as an intravenous treatment for acquired methaemoglobinaemia. It is separately sold as a research chemical and studied at low doses for mitochondrial and cognitive endpoints, which are not approved uses.
- [MGF](https://bestpeptidecalculator.app/library/mgf.md): Mechano growth factor is the IGF-1Ec splice variant induced by muscle loading. Research MGF peptides are not an FDA drug. WADA S2.
- [MK-677](https://bestpeptidecalculator.app/library/mk-677.md): Oral non-peptide GH secretagogue (ibutamoren) that raises GH and IGF-1. Not FDA-approved. WADA S2 names ibutamoren (MK-677).
- [Motixafortide](https://bestpeptidecalculator.app/library/motixafortide.md): CXCR4 antagonist peptide approved, in combination with filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma.
- [MOTS-C](https://bestpeptidecalculator.app/library/mots-c.md): A 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene, notable as an example of the mitochondrion signalling to the rest of the cell rather than only receiving instructions. It has been studied for effects on glucose utilisation and fatty-acid oxidation through AMPK activation in metabolic models. Circulating concentrations fall with age and rise with exercise. Research use only; no human trials have been published and it is not FDA-approved.
- [Myristoyl Pentapeptide-17](https://bestpeptidecalculator.app/library/myristoyl-pentapeptide-17.md): Lipidated pentapeptide used in eyelash and eyebrow conditioning products. Regulated as a cosmetic ingredient; not FDA-approved as a drug and not equivalent to prostaglandin analog lash treatments.
- [N-Acetyl Selank Amidate](https://bestpeptidecalculator.app/library/n-acetyl-selank-amidate.md): Chemically modified analog of Selank with N-terminal acetylation and C-terminal amidation, sold as a research chemical and commonly used intranasally. Not FDA-approved. Published research on this modified form specifically is very limited; most available data concerns Selank itself.
- [N-Acetyl Semax Amidate](https://bestpeptidecalculator.app/library/n-acetyl-semax-amidate.md): N-acetylated, C-amidated Semax analog sold for nootropic research, intended to resist peptidases versus standard Semax. Not FDA-approved.
- [NAD+ (Nicotinamide Adenine Dinucleotide)](https://bestpeptidecalculator.app/library/nad_plus.md): Essential redox cofactor sold as IV clinic infusions and oral precursors (NR/NMN). NAD+ itself is not FDA-approved as a drug for anti-aging.
- [Nafarelin](https://bestpeptidecalculator.app/library/nafarelin.md): Intranasally administered GnRH receptor agonist approved for endometriosis and for central precocious puberty. One of the few peptide drugs delivered routinely by nasal spray.
- [Noopept](https://bestpeptidecalculator.app/library/noopept.md): Synthetic dipeptide developed in Russia and marketed there as a nootropic. It is not FDA-approved and is not a lawful dietary supplement ingredient in the United States. Most published research is Russian-language and preclinical.
- [Octreotide](https://bestpeptidecalculator.app/library/octreotide.md): Synthetic cyclic octapeptide analog of somatostatin, engineered to resist degradation so its half-life is roughly ninety minutes rather than the two minutes of the natural hormone. FDA-approved for acromegaly, for symptom control in metastatic carcinoid tumours, and for the profuse watery diarrhoea of VIPoma. Because somatostatin is a broad inhibitory signal, it also suppresses insulin, glucagon and several gut hormones. A prescription medicine.
- [Orexin-A](https://bestpeptidecalculator.app/library/orexin-a.md): Endogenous 33-amino-acid hypothalamic neuropeptide central to arousal and wakefulness. Loss of orexin-producing neurons causes narcolepsy type 1. Studied as an intranasal research compound; not FDA-approved.
- [Orforglipron](https://bestpeptidecalculator.app/library/orforglipron.md): FDA-approved April 1, 2026 (Foundayo). Once-daily non-peptide oral GLP-1 receptor agonist for chronic weight management without food or water timing restrictions.
- [Ovagen](https://bestpeptidecalculator.app/library/ovagen.md): Ovagen is sold in the Khavinson bioregulator tradition as a liver or ovary bioregulator. Product descriptions give it either as the tripeptide Glu-Asp-Leu (EDL) or as a tissue-derived peptide complex, and no indexed paper settles which. The only indexed EDL work is in cell culture and rats. No controlled human evidence exists and it is not FDA-approved.
- [Oxyntomodulin](https://bestpeptidecalculator.app/library/oxyntomodulin.md): Naturally occurring 37-amino-acid gut hormone that activates both GLP-1 and glucagon receptors. It is the endogenous template for the dual-agonist drug class and is studied rather than marketed. Not FDA-approved.
- [Oxytocin](https://bestpeptidecalculator.app/library/oxytocin.md): FDA-approved nonapeptide (Pitocin) for labor induction/augmentation and postpartum hemorrhage. Intranasal research use for social cognition is not an approved indication.
- [P21 (BDNF-mimetic peptide)](https://bestpeptidecalculator.app/library/p21.md): Short nootropic peptide associated with Cerebrolysin-derived fragments in research catalogs. Distinct from the p21 CDK inhibitor protein. Not FDA-approved.
- [PACAP-38](https://bestpeptidecalculator.app/library/pacap-38.md): 38-aa neuropeptide that activates PAC1/VPAC receptors. Research tool in migraine, neuroprotection, and metabolic models. Not FDA-approved as a drug.
- [Palmitoyl Hexapeptide-12](https://bestpeptidecalculator.app/library/palmitoyl-hexapeptide-12.md): Palmitoylated hexapeptide used in topical anti-ageing formulations, frequently combined with other matrikines. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
- [Palmitoyl Pentapeptide-4](https://bestpeptidecalculator.app/library/palmitoyl-pentapeptide-4.md): Palmitoylated KTTKS matrikine (Matrixyl) used in anti-wrinkle cosmetics. Not an FDA drug. Not WADA-prohibited as a cosmetic peptide.
- [Palmitoyl Tetrapeptide-7](https://bestpeptidecalculator.app/library/palmitoyl-tetrapeptide-7.md): Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.
- [Palmitoyl Tripeptide-1](https://bestpeptidecalculator.app/library/palmitoyl-tripeptide-1.md): The GHK tripeptide supplied with a palmitic acid chain attached to improve penetration through the outer skin barrier, and without the bound copper of GHK-Cu. It is used topically as a matrikine, a peptide fragment that signals matrix turnover to dermal fibroblasts, and is most often formulated alongside palmitoyl tetrapeptide-7. Regulated as a cosmetic ingredient rather than a drug, and not FDA-approved for any therapeutic use.
- [Palmitoyl Tripeptide-5](https://bestpeptidecalculator.app/library/palmitoyl-tripeptide-5.md): Lipidated tripeptide marketed under the Syn-Coll name and used topically in firming and anti-ageing formulations. It is described as a thrombospondin-1 mimetic, intended to promote activation of transforming growth factor beta already present in the dermis rather than to supply new growth factor. Evidence comes predominantly from supplier research and small cosmetic studies. A cosmetic active, not a drug, and not FDA-approved.
- [Pancragen](https://bestpeptidecalculator.app/library/pancragen.md): Lys-Glu-Asp-Trp, a synthetic tetrapeptide in the Khavinson bioregulator series associated with pancreatic tissue, with reported effects on carbohydrate metabolism markers in animal models. It should not be confused with Suprefort, the tissue extract marketed for the same organ. The supporting literature is regional and uncontrolled, and it is not FDA-approved or a treatment for diabetes.
- [Pasireotide](https://bestpeptidecalculator.app/library/pasireotide.md): Somatostatin analog with a broader receptor binding profile than octreotide, approved for Cushing disease and for acromegaly in patients inadequately controlled by surgery or other somatostatin analogs.
- [PE-22-28](https://bestpeptidecalculator.app/library/pe-22-28.md): Shortened analog of spadin, a peptide derived from sortilin maturation, which blocks the TREK-1 potassium channel. Because mice lacking TREK-1 show a depression-resistant phenotype, the channel became an antidepressant target, and PE-22-28 produces antidepressant-like effects in rodents within days rather than the weeks required by monoamine reuptake inhibitors. Preclinical only, with no human trials, and not FDA-approved.
- [PEG-MGF (PEGylated Mechano Growth Factor)](https://bestpeptidecalculator.app/library/peg-mgf.md): PEGylated mechano-growth-factor (IGF-1Ec) analog sold for muscle-repair research. Not FDA-approved. WADA S2 (IGF / MGF).
- [Pegcetacoplan](https://bestpeptidecalculator.app/library/pegcetacoplan.md): FDA-approved pegylated peptide that inhibits complement C3, sold as Empaveli for PNH, C3G and primary IC-MPGN and as Syfovre for geographic atrophy. The two products differ in dose, route and schedule.
- [Pegvisomant](https://bestpeptidecalculator.app/library/pegvisomant.md): PEGylated growth hormone analog approved for acromegaly in patients with inadequate response to surgery, radiotherapy, or other medical therapy. It is a receptor antagonist rather than an agonist.
- [Pemvidutide](https://bestpeptidecalculator.app/library/pemvidutide.md): Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation.
- [Pentadeca Arginate](https://bestpeptidecalculator.app/library/pentadeca-arginate.md): Arginate salt form of the BPC-157 pentadecapeptide, marketed as a more stable alternative to the acetate salt. Not FDA-approved. Published research on the arginate form specifically is minimal; nearly all available evidence concerns BPC-157 itself.
- [Petrelintide](https://bestpeptidecalculator.app/library/petrelintide.md): Investigational long-acting amylin receptor agonist from Zealand Pharma, engineered for once-weekly dosing and in clinical development for obesity. Amylin agonists reduce food intake through hindbrain pathways separate from incretin signalling, so they are being studied both alone and alongside GLP-1 receptor agonists. Not FDA-approved.
- [Pinealon](https://bestpeptidecalculator.app/library/pinealon.md): Glu-Asp-Arg tripeptide from the Khavinson pineal series, studied for neuroprotection in older literature. Not FDA-approved.
- [Plecanatide](https://bestpeptidecalculator.app/library/plecanatide.md): Orally administered uroguanylin analog approved for chronic idiopathic constipation and for irritable bowel syndrome with constipation. Like linaclotide it acts locally on intestinal epithelium with minimal systemic exposure.
- [PNC-27](https://bestpeptidecalculator.app/library/pnc-27.md): Experimental peptide containing a p53 motif designed to lyse cancer-cell membranes in preclinical papers. Not FDA-approved; not a cancer treatment.
- [Pralmorelin (GHRP-2)](https://bestpeptidecalculator.app/library/pralmorelin-ghrp2.md): Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin).
- [Pramlintide](https://bestpeptidecalculator.app/library/pramlintide.md): FDA-approved amylin analog (Symlin) used with mealtime insulin in type 1 and type 2 diabetes. Hypoglycemia risk requires insulin dose reduction.
- [Prostamax](https://bestpeptidecalculator.app/library/prostamax.md): Prostamax is Lys-Glu-Asp-Pro (KEDP), a synthetic tetrapeptide sold as a prostate bioregulator in the Khavinson tradition. Its literature is cell-culture work, mostly on chromatin in lymphocytes from older people. It is not a treatment for benign prostatic hyperplasia or any other prostate condition, has no controlled trial evidence, and is not FDA-approved.
- [PTD-DBM](https://bestpeptidecalculator.app/library/ptd-dbm.md): Cell-penetrating peptide designed to block CXXC5–Dishevelled binding and enhance Wnt signaling in hair-growth mouse models. Not FDA-approved.
- [PTH(1-34) Analog (Generic Teriparatide)](https://bestpeptidecalculator.app/library/pth-1-34-analog.md): PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.
- [Relamorelin](https://bestpeptidecalculator.app/library/relamorelin.md): Investigational pentapeptide ghrelin receptor agonist developed principally for its gastrointestinal rather than endocrine effects. Ghrelin receptors on enteric neurons accelerate gastric emptying when activated, and relamorelin has been studied mainly in diabetic gastroparesis, where delayed emptying drives the symptoms. Clinical development has been mixed and it is not FDA-approved for any indication.
- [Retatrutide](https://bestpeptidecalculator.app/library/retatrutide.md): Lilly triple agonist (GIP, GLP-1, glucagon receptors). The first published phase 3 trial, TRANSCEND-T2D-1 (Lancet, 2026), lowered HbA1c and body weight over 40 weeks in type 2 diabetes; the TRIUMPH obesity trials have not yet published peer-reviewed results. Not FDA-approved.
- [Rusfertide](https://bestpeptidecalculator.app/library/rusfertide.md): FDA-approved hepcidin mimetic peptide (Mimrylo, August 2026) for erythrocytosis in adults with polycythemia vera. A weekly subcutaneous injection that limits the iron available for making red blood cells.
- [Secretin](https://bestpeptidecalculator.app/library/secretin.md): Synthetic human 27-amino-acid gastrointestinal hormone approved as a diagnostic agent to stimulate pancreatic secretions, to stimulate gastrin secretion in suspected gastrinoma, and to aid identification of the ampulla during endoscopy.
- [Selank](https://bestpeptidecalculator.app/library/selank.md): Synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a stabilising tail, developed in Russia as an anxiolytic and most often used intranasally. It has been studied for anxiety without the sedation or dependence associated with benzodiazepines, and retains some immune-modulating activity from its tuftsin origin. Not FDA-approved; the supporting clinical literature is largely Russian-language.
- [Semaglutide](https://bestpeptidecalculator.app/library/semaglutide.md): FDA-approved long-acting GLP-1 agonist for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). Weekly injection or daily oral tablet. Not WADA-prohibited (monitoring program).
- [Semaglutide & Tirzepatide](https://bestpeptidecalculator.app/library/semaglutide-tirzepatide.md): Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Each is approved on its own; the combination is not approved, and both labels say use with another GLP-1 receptor agonist is not recommended.
- [Semax](https://bestpeptidecalculator.app/library/semax.md): Synthetic analog of the ACTH(4-10) fragment with a stabilising tail added, developed in Russia and used there as an intranasal nootropic and neuroprotective agent for stroke and cognitive indications. It has no corticotropic activity despite its ACTH origin. Reported activity centres on brain-derived neurotrophic factor expression and monoamine modulation. Not FDA-approved, and the clinical literature is almost entirely Russian-language with limited independent replication.
- [Serelaxin](https://bestpeptidecalculator.app/library/serelaxin.md): Recombinant form of the human hormone relaxin-2, investigated for acute heart failure. A large phase 3 outcomes trial did not meet its primary endpoints and development was discontinued. Not FDA-approved.
- [Sermorelin](https://bestpeptidecalculator.app/library/sermorelin.md): GHRH(1-29), the shortest fragment of growth hormone-releasing hormone that retains full activity at the pituitary GHRH receptor. It was marketed in the United States as Geref for paediatric growth hormone deficiency and as a diagnostic agent; the brand was discontinued in 2008 for commercial rather than safety reasons, and it remains available through compounding pharmacies. Because it stimulates the pituitary rather than replacing the hormone, it requires an intact somatotroph axis. Prohibited in sport under WADA class S2.
- [Setmelanotide](https://bestpeptidecalculator.app/library/setmelanotide.md): FDA-approved MC4R agonist (Imcivree) for rare genetic obesities (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). Daily SC injection, not a general-obesity drug.
- [sh-Oligopeptide-1 (Human EGF)](https://bestpeptidecalculator.app/library/egf-oligopeptide-1.md): Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.
- [SLU-PP-332](https://bestpeptidecalculator.app/library/slu-pp-332.md): Pan-estrogen-related-receptor agonist studied as an exercise mimetic in mice (2023). Not a peptide and not FDA-approved.
- [Somapacitan](https://bestpeptidecalculator.app/library/somapacitan.md): Once-weekly albumin-binding growth hormone derivative approved for growth hormone deficiency in adults and in children. It reduces injection frequency from daily to weekly.
- [Somatrogon](https://bestpeptidecalculator.app/library/somatrogon.md): Long-acting recombinant human growth hormone in which the hormone is fused to three copies of the C-terminal peptide of the chorionic gonadotropin beta subunit. The added glycosylation slows clearance enough for once-weekly rather than daily injection. Marketed as Ngenla and FDA-approved for growth hormone deficiency in children, it is a prescription medicine.
- [SS-20](https://bestpeptidecalculator.app/library/ss-20.md): Mitochondria-targeted tetrapeptide from the same Szeto-Schiller series as elamipretide, distinguished by lacking the dimethyltyrosine residue that gives elamipretide its cardiolipin affinity. Not FDA-approved; preclinical only.
- [Suprefort](https://bestpeptidecalculator.app/library/suprefort.md): Peptide preparation derived from pancreatic tissue and marketed as a pancreatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Suprefort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.
- [Survodutide](https://bestpeptidecalculator.app/library/survodutide.md): Investigational dual agonist at the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma and studied in phase 3 trials for obesity and for metabolic dysfunction-associated steatohepatitis. The glucagon component acts directly on hepatocytes to increase energy expenditure and fat oxidation, which is why liver endpoints feature alongside weight. Not FDA-approved for any indication.
- [Svetinorm](https://bestpeptidecalculator.app/library/svetinorm.md): Peptide preparation derived from liver tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Svetinorm itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [Tabimorelin](https://bestpeptidecalculator.app/library/tabimorelin.md): Orally active growth hormone secretagogue investigated for growth hormone deficiency. Development was discontinued. Not FDA-approved.
- [TB-500 (Thymosin Beta-4 fragment)](https://bestpeptidecalculator.app/library/tb-500.md): Usually sold as an acetylated thymosin-β4 actin-binding fragment (LKKTETQ), not full-length Tβ4. Not FDA-approved. Related to prohibited thymosin-β4 use in sport.
- [Teduglutide](https://bestpeptidecalculator.app/library/teduglutide.md): Recombinant analog of glucagon-like peptide-2 approved for adults and children with short bowel syndrome who depend on parenteral support. It is the only approved peptide acting specifically on intestinal mucosal growth.
- [Teriparatide](https://bestpeptidecalculator.app/library/teriparatide.md): FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk.
- [Terlipressin](https://bestpeptidecalculator.app/library/terlipressin.md): Synthetic vasopressin prodrug approved in the United States to improve kidney function in adults with hepatorenal syndrome and rapid reduction in renal function. Used more widely outside the US for variceal bleeding.
- [Tesamorelin](https://bestpeptidecalculator.app/library/tesamorelin.md): FDA-approved GHRH analog (Egrifta) to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. WADA still prohibits tesamorelin (S2) in sport.
- [Tesofensine](https://bestpeptidecalculator.app/library/tesofensine.md): Small-molecule triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated for obesity. Not FDA-approved. It is widely sold as a research chemical despite having no approved indication in the United States.
- [Testagen](https://bestpeptidecalculator.app/library/testagen.md): Short peptide sold as a testicular/endocrine bioregulator. Not FDA-approved; not a testosterone secretagogue with modern RCT evidence.
- [Testoluten](https://bestpeptidecalculator.app/library/testoluten.md): Peptide preparation derived from testicular tissue and sold as a male endocrine bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, and is distinct from Testagen, the synthetic tetrapeptide associated with the same tissue. It is not a treatment for hypogonadism or a substitute for testosterone therapy, and it is not FDA-approved. No study of Testoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.
- [Thymalin](https://bestpeptidecalculator.app/library/thymalin.md): Thymus-derived polypeptide preparation used in some countries as an immunomodulator. Not FDA-approved; composition is an extract, not a single sequence.
- [Thymogen (Oglufanide)](https://bestpeptidecalculator.app/library/thymogen.md): Glu-Trp, a synthetic dipeptide identified as the active fragment of thymopoietin and also known as oglufanide. Despite its very small size it has been studied as an immunomodulator affecting T-cell differentiation and innate immune function, and is used in some CIS markets for that purpose. Its plasma half-life is measured in minutes, which constrains how it can be given. Not FDA-approved.
- [Thymolin](https://bestpeptidecalculator.app/library/thymolin.md): Vendor thymic-immune peptide listing; identity may overlap thymulin/thymogen/thymalin depending on supplier. Not FDA-approved.
- [Thymopentin](https://bestpeptidecalculator.app/library/thymopentin.md): Synthetic pentapeptide corresponding to residues 32 to 36 of thymopoietin, the fragment that carries its immunologically active sequence. Used in some countries as an immunomodulator; not FDA-approved.
- [Thymosin Alpha-1](https://bestpeptidecalculator.app/library/thymosin-alpha-1.md): 28-aa thymic peptide (thymalfasin). Approved in several countries (Zadaxin) for hepatitis B and as an immune adjuvant; not FDA-approved in the US.
- [Thymosin β4 (Tβ4)](https://bestpeptidecalculator.app/library/thymosin-beta-4.md): 43-aa G-actin-sequestering peptide studied for wound healing and cardiac repair (timbetasin programs). Not FDA-approved. Distinct from the shorter TB-500 fragment.
- [Thymulin](https://bestpeptidecalculator.app/library/thymulin.md): Zinc-dependent thymic nonapeptide, also called facteur thymique serique, secreted by thymic epithelial cells. It is biologically inactive until zinc binds and fixes it in the active conformation, so its activity tracks zinc status as well as peptide concentration. It has been studied for T-cell differentiation and, separately, for anti-inflammatory and antinociceptive effects in animal models. Circulating levels fall with age as the thymus involutes. Not FDA-approved as a drug.
- [Thyreogen](https://bestpeptidecalculator.app/library/thyreogen.md): Peptide preparation derived from thyroid tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Thyreogen itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [Thyrotropin Alfa](https://bestpeptidecalculator.app/library/thyrotropin-alfa.md): Recombinant human thyroid-stimulating hormone approved as an adjunctive diagnostic for serum thyroglobulin testing with or without radioiodine imaging, and as an adjunct to radioiodine ablation of thyroid remnant tissue.
- [Tirzepatide](https://bestpeptidecalculator.app/library/tirzepatide.md): FDA-approved weekly dual GIP/GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and obesity (Zepbound). Not WADA-prohibited (monitoring).
- [Trifluoroacetyl Tripeptide-2](https://bestpeptidecalculator.app/library/trifluoroacetyl-tripeptide-2.md): Fluorinated tripeptide marketed in topical firming products, sold commercially under the Progeline name. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
- [Triptorelin](https://bestpeptidecalculator.app/library/triptorelin.md): FDA-approved depot GnRH agonist (Trelstar) for advanced prostate cancer. Causes flare then downregulation of LH/testosterone. WADA S2.
- [Trofinetide](https://bestpeptidecalculator.app/library/trofinetide.md): FDA-approved treatment for Rett syndrome (Daybue, Daybue Stix) in adults and children aged 2 and older. A synthetic analog of a tripeptide from IGF-1, taken twice daily by weight, and its mechanism is unknown.
- [Tuftsin](https://bestpeptidecalculator.app/library/tuftsin.md): Naturally occurring tetrapeptide derived from the Fc region of immunoglobulin G, studied for effects on phagocytes. It is the structural parent of Selank. Not FDA-approved.
- [Vasoactive Intestinal Peptide (VIP)](https://bestpeptidecalculator.app/library/vip.md): 28-aa neuropeptide vasodilator and VPAC agonist. Aviptadil (synthetic VIP) has been studied in pulmonary settings but VIP itself is not an FDA-approved general-use drug.
- [Vasopressin](https://bestpeptidecalculator.app/library/vasopressin.md): Endogenous nonapeptide hormone, available as a prescription intravenous product, approved to raise blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
- [Ventfort](https://bestpeptidecalculator.app/library/ventfort.md): Peptide preparation derived from vascular tissue and sold as a cardiovascular bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, and is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. No study of Ventfort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators, and it is not FDA-approved.
- [Vesugen](https://bestpeptidecalculator.app/library/vesugen.md): Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved.
- [Vilon](https://bestpeptidecalculator.app/library/vilon.md): Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved.
- [VK2735](https://bestpeptidecalculator.app/library/vk2735.md): Investigational dual agonist of the GLP-1 and GIP receptors in clinical development for obesity and metabolic disease, in both injectable and oral formulations. Not FDA-approved.
- [Vladonix](https://bestpeptidecalculator.app/library/vladonix.md): Peptide preparation derived from thymus tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Vladonix itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [Vosoritide](https://bestpeptidecalculator.app/library/vosoritide.md): Analog of C-type natriuretic peptide approved to increase linear growth in children with achondroplasia who have open epiphyses.
- [Wolverine Stack](https://bestpeptidecalculator.app/library/wolverine-stack.md): Common shop blend of BPC-157 plus TB-500. Not a single API. Both components are unapproved and WADA-relevant (BPC-157 is S0; TB-500/Tβ4 is prohibited-class).
- [Zhenoluten](https://bestpeptidecalculator.app/library/zhenoluten.md): Peptide preparation derived from female reproductive tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Zhenoluten itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
- [Ziconotide](https://bestpeptidecalculator.app/library/ziconotide.md): Synthetic equivalent of a cone snail venom peptide, approved for severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments.
- [Zilucoplan](https://bestpeptidecalculator.app/library/zilucoplan.md): FDA-approved macrocyclic peptide (Zilbrysq) that inhibits complement C5, for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. A daily self-injection with a boxed warning for meningococcal infection.
- [Zinc Thymulin](https://bestpeptidecalculator.app/library/zinc-thymulin.md): Zinc-complexed form of thymulin, the thymic nonapeptide that requires bound zinc for biological activity. Investigated for immune modulation and, topically, for hair growth. Not FDA-approved.